Ola Landgren

Clinical Advisor at Cellectis

Professor Ola Landgren, MD, is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center New York and Professor of Medicine at Weill Cornell Medical College. He is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring. He has a strong interest in the development of early-treatment clinical trials, targeting high-risk smoldering myeloma. He develops new strategies (including cell-based, molecular-based, and imaging-based) and implements advanced MRD testing in clinical trials at MSK.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Cellectis

1 followers

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.


Industries

Headquarters

Paris, France

Employees

51-200

Links